Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Survivin Essential for the Maturation of Antigen Presenting Cells in Rheumatoid Arthritis Patients

Lara C. Pullen, PhD  |  January 2, 2013

When asked about the clinical implications of her study, Dr. Bokarewa responded by e-mail that, “For general practitioners and for rheumatologists, I would recommend to test the levels of survivin in blood circulation. High levels will indicate patients with severe and joint-destructive disease. High levels of survivin are tightly connected with progression of joint destruction and poor response to antirheumatic treatment. It is a valuable parameter to analyze in parallel with such accredited parameters as rheumatoid factor and antibodies to cyclic citrulinated peptides.”

She added, “We have preliminary data which would show that survivin (or survivin-related proteins) is a promising therapeutic target in arthritis.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

 

Dr. Pullen is a medical writer based in the Chicago area.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Reference

1. Andersson SE, Svensson MN, Erlandsson MC, Dehlin M, Andersson KM, Bokarewa MI. Activation of Fms-like tyrosine kinase 3 signaling enhances survivin expression in a mouse model of rheumatoid arthritis. PLoS One. 2012;7:e47668.

 

Page: 1 2 | Single Page
Share: 

Filed under:ConditionsResearch RheumRheumatoid Arthritis Tagged with:RARheumatoid arthritis

Related Articles

    A Duet of Bone and the Immune System

    July 12, 2011

    Examining emerging perspectives in osteoimmunology

    T Cells in Systemic Lupus Erythematosus

    August 1, 2011

    Progress toward targeted therapy

    A&R Abstracts – T CELLS

    August 1, 2011

    For Further Reading

    Dendritic Cells as Therapeutics: The New Frontier

    August 26, 2020

    Cancer treatments, organ transplants and rheumatologic diseases—dendritic cells are being used throughout medicine to create innovative treatments, according to presenters of a virtual session during the European e-Congress of Rheumatology.

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences